EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Evaluation of the Novel Benzimidazole Derivatives Inspired YC‐1 as HIF‐1α Inhibitor That Possess Anti‐Colon Cancer Potential

Qixian Yang, Jing Zhang, Meijing Liu, Xiangping Deng, Zhizhong Xie, Xiaoyong Lei iD, Xiaoyan Yang iD, Guotao Tang, Zhe Wang

Drug Development Research · 2026

DOI: 10.1002/ddr.70347 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Qixian Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Provincial Key Laboratory of Basic and Clinical Pharmacological Research of Gastrointestinal Cancer, Department of Pharmacy, Institute of Pharm…. Hauptthemen laut MEDLINE: Hypoxia-Inducible Factor 1, alpha Subunit, Indazoles, Antineoplastic Agents, Benzimidazoles. Die Arbeit nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province, Scientific Research Fund of Hunan Provincial Education Department.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia‐inducible factor‐1 α (HIF‐1α) is a key transcription factor for tumor cells to sense and adapt to the hypoxic microenvironment, regulate tumor progression such as tumor glycolysis, and is an important target for the development of anti‐tumor drugs. YC‐1 (1‐benzyl‐3‐(5’‐hydroxymethyl‐2’‐furyl)indazole), as a classic inhibitor of HIF‐1α, has received extensive attention in multiple anti‐tumor studies. Some derivatives that replace YC‐1 indazole with the benzimidazole skeleton have shown certain HIF‐1α inhibitory and anti‐tumor potential. In this study, a series of substituted benzimidazole derivatives were designed and synthesized, and their HIF‐1α inhibitory and anti‐tumor effects were screened and investigated. In vitro anti‐proliferation and dual‐luciferase reports showed that compound 9o had superior in vitro anti‐tumor (IC 50 = 33.85 μM) and HIF‐1α transcriptional inhibitory activity (79.59% inhibition rate) compared with the positive control YC‐1. Meanwhile, compound 9o can also significantly inhibit the colony formation and survival rate of HCT‐116 cells. In addition, Western blotting, real‐time PCR and and lactic acid content experiments verified its inhibitory effect on HIF‐1α and downstream glycolysis. In addition, compound 9o was found to reduce platelet aggregation more than YC‐1, and the molecular docking results suggested that compound 9o weakened its interaction with soluble guanylate cyclase (sGC), which is beneficial for avoiding the bleeding risk during tumor treatment. In vivo studies have shown that compound 9o can inhibit tumor growth and reduce the levels of HIF‐1α and glycolysis rate‐limiting enzyme HK2 in HCT‐116 tumor‐bearing mice. The acute toxicity results also demonstrated the safety of compound 9o in vivo. Finally, we also explored its pharmacokinetic properties in rats, suggesting its potential for subsequent intravenous administration. These findings provide a basis for the further discovery of anti‐tumor candidate compounds based on HIF‐1α inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoxia-Inducible Factor 1, alpha SubunitIndazolesAntineoplastic AgentsBenzimidazolesColonic NeoplasmsHumansAnimalsDrug DesignCell ProliferationCell Line, TumorMiceMice, NudeMolecular Docking SimulationMice, Inbred BALB CMale

Stichwörter der Autor:innen

HIF‐1αanti‐tumorbenzimidazole derivativesglycolysisin vivo

Substanzen

Hypoxia-Inducible Factor 1, alpha Subunit3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazoleIndazolesAntineoplastic AgentsBenzimidazolesHIF1A protein, human

Autor:innen und Institutionen

  • Hunan Provincial Key Laboratory of Basic and Clinical Pharmacological Research of Gastrointestinal Cancer, Department of Pharmacy, Institute of Pharmacy and Pharmacology, The Second Affiliated Hospital, University of So…
  • School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
  • Hengyang Medical School, University of South China, Hengyang, Hunan, China.
  • Department of Pharmacy, The First Affiliated Hospital, University of South China, Hengyang, Hunan, China.
  • The College of Pharmacy, Xiangnan University, Chenzhou, Hunan, China.

ORCID-Profile: Xiaoyong Lei, Xiaoyan Yang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province
  • Scientific Research Fund of Hunan Provincial Education Department
  • Foundation of Hunan Provincial Key Laboratory
  • Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study
  • Tumor Microenvironment Responsive to Natural Product R&D Graduate Innovation Base

Zitieren

APA

Yang, Q., Zhang, J., Liu, M., Deng, X., Xie, Z., Lei, X., Yang, X., Tang, G., & Wang, Z. (2026). Design, Synthesis, and Evaluation of the Novel Benzimidazole Derivatives Inspired YC‐1 as HIF‐1α Inhibitor That Possess Anti‐Colon Cancer Potential. Drug Development Research. https://doi.org/10.1002/ddr.70347

Vancouver

Yang Q, Zhang J, Liu M, Deng X, Xie Z, Lei X, et al. Design, Synthesis, and Evaluation of the Novel Benzimidazole Derivatives Inspired YC‐1 as HIF‐1α Inhibitor That Possess Anti‐Colon Cancer Potential. Drug Development Research. 2026. doi:10.1002/ddr.70347

BibTeX
@article{Yang2026,
  author = {Yang, Qixian and Zhang, Jing and Liu, Meijing and Deng, Xiangping and Xie, Zhizhong and Lei, Xiaoyong and Yang, Xiaoyan and Tang, Guotao and Wang, Zhe},
  title = {Design, Synthesis, and Evaluation of the Novel Benzimidazole Derivatives Inspired YC‐1 as HIF‐1α Inhibitor That Possess Anti‐Colon Cancer Potential},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70347}
}
Kostenlos starten →